TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

Pediatr Blood Cancer. 2015 Jun;62(6):1058-60. doi: 10.1002/pbc.25327. Epub 2014 Nov 14.

Abstract

We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.

Keywords: MRD; PDGFRB fusion; Ph-like ALL; TKI; genomic PCR.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Dasatinib
  • Humans
  • Male
  • Neoplasm, Residual
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrimidines / therapeutic use*
  • Receptor, Platelet-Derived Growth Factor beta / genetics*
  • Repressor Proteins
  • Thiazoles / therapeutic use*
  • Transcription Factors / genetics*
  • Translocation, Genetic*

Substances

  • ATF7IP protein, human
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Repressor Proteins
  • Thiazoles
  • Transcription Factors
  • Protein-Tyrosine Kinases
  • Receptor, Platelet-Derived Growth Factor beta
  • Dasatinib